ArticleOncoTargets and therapy2018

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.

Junsheng Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.